Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY.
JCO Clin Cancer Inform. 2023 Aug;7:e2300086. doi: 10.1200/CCI.23.00086.
We described information technology support and use of telemedicine for cancer care and research purposes at community oncology practices within the National Cancer Institute Community Oncology Research Program (NCORP).
We used data from the NCORP 2017 and 2022 Landscape Assessments. Separate logistic regression models were used to assess factors associated with the use of telemedicine for delivery of cancer care in 2017 and for research purposes in 2022 (cancer care delivery not assessed in 2022).
Information was available from 210 and 259 practice groups excluding pediatric-only groups in 2017 and 2022, respectively. In 2017, 30% of practice groups used telemedicine for delivery of cancer care; half of these (15% overall) could use telemedicine for research purposes. In 2022, telemedicine was used for research purposes in 73% of practice groups. In multivariable models, self-identifying as a safety-net hospital was associated with a lower odd of telemedicine use for delivery of cancer care (adjusted odds ratio [AOR], 0.39; 95% CI, 0.17 to 0.93), whereas affiliation with a designated critical access hospital was associated with a higher odd of telemedicine use for delivery of cancer care (AOR, 2.29; 95% CI, 1.10 to 4.76). Having a general survivorship clinic (AOR, 1.92; 95% CI, 1.04 to 3.54) and number of oncology providers (increase per 10 providers; AOR, 1.32; 95% CI, 1.05 to 1.65) were associated with telemedicine use for research purposes.
Almost one third of NCORP practice groups used telemedicine for cancer care delivery in 2017. In 2022, there is high capacity among NCORP practices (almost three-quarters) to use telemedicine for research purposes, especially among practices with a general survivorship clinic and a greater provider number.
我们描述了美国国立癌症研究所社区肿瘤学研究计划(NCORP)中社区肿瘤学实践中癌症护理和研究目的的信息技术支持和远程医疗使用情况。
我们使用了来自 NCORP 2017 年和 2022 年景观评估的数据。我们分别使用逻辑回归模型评估了与 2017 年癌症护理交付以及 2022 年研究目的相关的因素(2022 年未评估癌症护理交付)。
2017 年和 2022 年分别有 210 个和 259 个实践小组(不包括仅儿科的小组)提供了信息。2017 年,30%的实践小组使用远程医疗进行癌症护理;其中一半(总体占 15%)可以将远程医疗用于研究目的。2022 年,73%的实践小组将远程医疗用于研究目的。在多变量模型中,自我认定为安全网医院与癌症护理远程医疗使用率较低相关(调整后的优势比 [AOR],0.39;95%置信区间,0.17 至 0.93),而与指定的关键访问医院的隶属关系与癌症护理远程医疗使用率较高相关(AOR,2.29;95%置信区间,1.10 至 4.76)。拥有一般生存诊所(AOR,1.92;95%置信区间,1.04 至 3.54)和肿瘤学提供者数量(每增加 10 名提供者;AOR,1.32;95%置信区间,1.05 至 1.65)与远程医疗用于研究目的有关。
2017 年,近三分之一的 NCORP 实践小组使用远程医疗进行癌症护理。2022 年,NCORP 实践中(近四分之三)有很高的能力将远程医疗用于研究目的,特别是在拥有一般生存诊所和更多提供者数量的实践中。